

**REMARKS**

Reconsideration is requested.

Claim 47 has been canceled, without prejudice, and claim 23 has been amended to include the details of the same. Claim 23 has been further revised, without prejudice, to specify that the administered composition consists essentially of the recited therapeutically active ingredient(s). Claims 23, 31 and 48 have been revised, without prejudice, to recite the vitamin C and derivatives thereof as therapeutically active ingredients. No new matter has been added.

The Section 103 rejection of claims 23, 29, 31, 47 and 48 over Baxter (U.S. Patent Application Publication No. 2002/0198236) in view of Cupps (U.S. Patent No. 6,486,190), is traversed. Reconsideration and withdrawal of the rejection are requested in view of the above and the distinguishing remarks of the Response filed June 17, 2009..

In addition to the remarks of record, the applicants submit that Baxter fails to teach or suggest a method of the claims wherein a composition containing a therapeutically active ingredient of the claims is administered for treatment of the recited disease. The secondary reference fails to cure these deficiencies of Baxter.

Withdrawal of the Section 103 rejection is requested.

The claims are submitted to be in condition for allowance and a Notice to that effect is requested. The Examiner is requested to contact the undersigned, preferably by telephone, in the event anything further is required in this regard.

FONTES et al.  
Appl. No. 10/521,239  
Attny. Ref.: 3665-132  
Amendment  
June 26, 2009

Respectfully submitted,

**NIXON & VANDERHYE P.C.**

By:                     /B. J. Sadoff/                      
B. J. Sadoff  
Reg. No. 36,663

BJS:  
901 North Glebe Road, 11th Floor  
Arlington, VA 22203-1808  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100